At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 ... the difference between integrating as we moved it from G6 to G7. That was quite a big lift for our ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

March 7 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key ...

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom DXCM revealed 12 unusual trades. Delving into the details, we found 33% of traders were ...

DexCom DXCM0.71%increase; green up pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...

2025 Adjusted EBITDA Guidance: Approximately 30%. DexCom Inc (NASDAQ:DXCM) reported an 8% organic revenue growth in Q4 2024, aligning with their guidance. The company expanded its global customer ...